Suchergebnisse - "Drew, Yvette"

PubPharm (64)

1

Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Jamieson, A. | Sobral de Barros, J. | Cochrane, D. | +11

2

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer : A Phase II Multi-Cohort Study

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2024

von Drew, Y. | Kim, J. | Penson, R. | +25

3

Temporal and disease-site specific transcriptional and phenotypic changes in response to neoadjuvant chemotherapy in high-grade serous ovarian cancers

enthalten in: ResearchSquare.com | 2023

von Saha, S. | Gentles, L. | Howarth, R. | +5

4

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer : final results from Study 10

enthalten in: British journal of cancer | 2023

von Kristeleit, R. | Drew, Y. | Oza, A. | +13

5

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer : Results from Cohort E of the Phase I GARNET Trial

enthalten in: Clinical lung cancer | 2022

von Moreno, V. | Roda, D. | Pikiel, J. | +15

6

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors : Implications for Combinations and Scheduling

enthalten in: Cancers | 2022

von Smith, H. | Willmore, E. | Mukhopadhyay, A. | +2

7

The Role of ATR Inhibitors in Ovarian Cancer : Investigating Predictive Biomarkers of Response

enthalten in: Cells | 2022

von Bradbury, A. | Zenke, F. | Curtin, N. | +1

8

A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours

enthalten in: British journal of cancer | 2022

von El Helali, A. | Plummer, R. | Jayson, G. | +10

9

British Gynaecological Cancer Society (BGCS) uterine cancer guidelines : Recommendations for practice

enthalten in: European journal of obstetrics, gynecology, and reproductive biology | 2022

von Morrison, J. | Balega, J. | Buckley, L. | +17

10

Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling

enthalten in: bioRxiv.org | 2022

von Smith, H. | Willmore, E. | Mukhopadhyay, A. | +2

1
2
3
4
5
6
7
Nächster »
[7]